Abstract
Nasolacrimal duct obstruction is often seen in patients with cancer. Iatrogenic causes such as surgery, radiation therapy, and chemotherapy are among the most common causes. Primary lacrimal drainage tumors are less common causes. The evaluation of patients with suspected nasolacrimal duct obstruction should include a thorough history and a comprehensive ophthalmic examination, including probing and irrigation of the lacrimal drainage apparatus and a Schirmer’s test. Imaging studies may also be necessary. Treatment depends on the degree and location of the obstruction and may consist of probing and irrigation alone; balloon dilation; intubation of the drainage system with silicone stents; or dacryocystorhinostomy, usually with placement of silicone stents to maintain duct patency during healing.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bartley GB. Acquired lacrimal drainage obstruction: an etiologic classification system, case reports, and a review of the literature. Part 1. Ophthal Plast Reconstr Surg 1992;8:237–42.
Bartley GB. Acquired lacrimal drainage obstruction: an etiologic classification system, case reports, and a review of the literature. Part 2. Ophthal Plast Reconstr Surg 1992;8:243–9.
Bartley GB. Acquired lacrimal drainage obstruction: an etiologic classification system, case reports, and a review of the literature. Part 3. Ophthal Plast Reconstr Surg 1993;9:11–26.
Lee-Wing MW, Ashenhurst ME. Clinicopathologic analysis of 166 patients with primary acquired nasolacrimal duct obstruction. Ophthalmology 2001;108:2038–40.
Valenzuela AA, McNab AA, Selva D, et al. Clinical features and management of tumors affecting the lacrimal drainage apparatus. Ophthal Plast Reconstr Surg 2006;22:96–101.
Stefanyszyn MA, Hidayat AA, Pe’er JJ, et al. Lacrimal sac tumors. Ophthal Plast Reconstr Surg 1994;10:169–84.
Yip CC, Bartley GB, Habermann TM, et al. Involvement of the lacrimal drainage system by leukemia or lymphoma. Ophthal Plast Reconstr Surg 2002;18:242–6.
Wladis EJ, Frempong T, Gausas R. Nasolacrimal metastasis from hepatocellular carcinoma masquerading as dacryocystitis. Ophthal Plast Reconstr Surg 2007;23:333–5.
Diba R, Saadati H, Esmaeli B. Outcomes of dacryocystorhinostomy in patients with head and neck tumors. Head Neck 2005;27:72–5.
Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002;87:5817–20.
Shepler TR, Sherman SI, Faustina MM, et al. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthal Plast Reconstr Surg 2003;19:479–81.
Morgenstern KE, Vadysirisack DD, Zhang Z, et al. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthal Plast Reconstr Surg 2005;21:337–44.
Haidak DJ, Hurwitz BS, Yeung KY. Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil. Ann Intern Med 1978;88:657.
Caravella LP Jr, Burns JA, Zangmeister M. Punctal–canalicular stenosis related to systemic fluorouracil therapy. Arch Ophthalmol 1981;99:284–6.
Eiseman AS, Flanagan JC, Brooks AB, et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg 2003;19(3):216–24.
Esmaeli B, Ahmadi MA, Rivera E, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002;120:1180–2.
Esmaeli B, Burnstine MA, Ahmadi MA, et al. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthal Plast Reconstr Surg 2003;19:305–8.
Esmaeli B, Amin S, Valero V, et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 2006;24:3619–22.
Esmaeli B, Hidaji L, Adinin RB, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003;98:504–7.
Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving weekly docetaxel. Arch Ophthalmol 2001;119:1802–4.
McCartney E, Valluri S, Rushing D, et al. Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel. Ophthal Plast Reconstr Surg 2007;23:170–1.
Billing K, Karagiannis A, Selva D. Punctal–canalicular stenosis associated with mitomycin-C for corneal epithelial dysplasia. Am J Ophthalmol 2003;136(4):746–7.
Kopp ED, Seregard S. Epiphora as a side effect of topical mitomycin C. Br J Ophthalmol 2004;88(11):1422–4.
Esmaeli B, Golio D, Lubecki L, et al. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol 2005;140:325–7.
Lim C, Martin P, Benger R, et al. Lacrimal canalicular bypass surgery with the Lester Jones tube. Am J Ophthalmol 2004;137:101–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Savar, A., Esmaeli, B. (2010). Nasolacrimal Duct Obstruction and Lacrimal Surgery in Cancer Patients. In: Esmaeli, B. (eds) Ophthalmic Oncology. M.D. Anderson Solid Tumor Oncology Series, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0374-7_19
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0374-7_19
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-0373-0
Online ISBN: 978-1-4419-0374-7
eBook Packages: MedicineMedicine (R0)